7 results on '"Nanegrungsunk D"'
Search Results
2. Preoperative Care Practice for Female Cardiac Patients: A Survey From the Society of Cardiovascular Anesthesiologists.
- Author
-
Nanegrungsunk D, Patel S, Jan T, and Ngai JY
- Subjects
- Female, Heart, Humans, Preoperative Care, Surveys and Questionnaires, Anesthesiologists, Anesthesiology
- Published
- 2022
- Full Text
- View/download PDF
3. Subarachnoid hemorrhage in C57BL/6J mice increases motor stereotypies and compulsive-like behaviors.
- Author
-
Nanegrungsunk D, Ragozzino ME, Xu HL, Haselton KJ, and Paisansathan C
- Subjects
- Animals, Anxiety etiology, Cognitive Dysfunction etiology, Depression etiology, Mice, Mice, Inbred C57BL, Subarachnoid Hemorrhage pathology, Compulsive Behavior etiology, Stereotypic Movement Disorder etiology, Subarachnoid Hemorrhage complications
- Abstract
Objective: Long-term behavioral, mood, and cognitive deficits affect over 30% of patients with subarachnoid hemorrhage (SAH). The aim of the present study was to examine the neurobehavioral outcomes following endovascular perforation induced SAH in mice., Methods: C57BL/6 J (B6) mice were exposed to endovascular perforation induced SAH or control surgery. Three weeks later, mice received a series of behavioral tests, e.g. motor function, stereotypy, learning, memory, behavioral flexibility, depression and anxiety. The immunohistologic experiment examined neuronalloss in the cortex following SAH., Results: SAH mice exhibited increased marble burying and nestlet shredding compared to that of control mice. Although SAH did not affect memory, learning or reversal learning,mice displayed greater overall object exploration in the novel object recognition test, as well as elevated perseveration during probabilistic reversal learning.In the forced swim and open field tests, SAH mice performed comparably to that of control mice. However, SAH mice exhibited an increased frequency in 'jumping' behavior in the open field test. Histological analyses revealed reduced neuron density in the parietal-entorhinal cortices of SAH mice on the injured side compared to that of control mice., Discussion: The findings suggest that parietal-entorhinal damage from SAH increases stereotyped motor behaviors and 'compulsive-like' behaviors without affecting cognition (learning and memory) or mood (anxiety and depression). This model can be used to better understand the neuropathophysiology following SAH that contributes to behavioral impairments in survivors with no gross sensory-motor deficits.
- Published
- 2021
- Full Text
- View/download PDF
4. Heparanase promotes neuroinflammatory response during subarachnoid hemorrhage in rats.
- Author
-
Changyaleket B, Chong ZZ, Dull RO, Nanegrungsunk D, and Xu H
- Subjects
- Animals, Inflammation enzymology, Inflammation pathology, Male, Random Allocation, Rats, Rats, Sprague-Dawley, Glucuronidase biosynthesis, Subarachnoid Hemorrhage enzymology, Subarachnoid Hemorrhage pathology
- Abstract
Background: Heparanase, a mammalian endo-β-D-glucoronidase that specifically degrades heparan sulfate, has been implicated in inflammation and ischemic stroke. However, the role of heparanase in neuroinflammatory response in subarachnoid hemorrhage (SAH) has not yet been investigated. This study was designed to examine the association between heparanase expression and neuroinflammation during subarachnoid hemorrhage., Methods: Rats were subjected to SAH by endovascular perforation, and the expression of heparanase was determined by Western blot analysis and immunofluorescence in the ipsilateral brain cortex at 24 h post-SAH. Pial venule leukocyte trafficking was monitored by using intravital microscopy through cranial window., Results: Our results indicated that, compared to their sham-surgical controls, the rats subjected to SAH showed marked elevation of heparanase expression in the ipsilateral brain cortex. The SAH-induced elevation of heparanase was accompanied by increased leukocyte trafficking in pial venules and significant neurological deficiency. Intracerebroventricular application of a selective heparanase inhibitor, OGT2115, which was initiated at 3 h after SAH, significantly suppressed the leukocyte trafficking and improved the neurological function., Conclusions: Our findings indicate that heparanase plays an important role in mediating the neuroinflammatory response after SAH and contributes to SAH-related neurological deficits and early brain injury following SAH.
- Published
- 2017
- Full Text
- View/download PDF
5. Bevacizumab is superior to Temozolomide in causing mitochondrial dysfunction in human brain tumors.
- Author
-
Nanegrungsunk D, Apaijai N, Yarana C, Sripetchwandee J, Limpastan K, Watcharasaksilp W, Vaniyapong T, Chattipakorn N, and Chattipakorn SC
- Subjects
- Calcium Chloride pharmacology, Dacarbazine pharmacology, Dose-Response Relationship, Drug, Edema chemically induced, Female, Humans, Male, Membrane Potential, Mitochondrial drug effects, Microscopy, Electron, Transmission, Mitochondria metabolism, Mitochondria pathology, Mitochondria ultrastructure, Reactive Oxygen Species metabolism, Retrospective Studies, Temozolomide, Tumor Cells, Cultured, Angiogenesis Inhibitors pharmacology, Antineoplastic Agents, Alkylating pharmacology, Bevacizumab pharmacology, Brain Neoplasms pathology, Dacarbazine analogs & derivatives, Mitochondria drug effects
- Abstract
Objective: Current chemotherapy treatments available for treating high-grade brain tumors, Temozolomide (TMZ) or Bevacizumab (BEV), not only have specific anti-tumor mechanisms, but also have an effect on mitochondria. However, effects of both drugs on mitochondria isolated from human brain tumors have not been thoroughly investigated. This study determined the direct effects of TMZ and BEV as well as the neurotoxic condition (calcium overload), on the function of mitochondria and compared these effects on mitochondria isolated from low- and high-grade human brain tumors., Methods: Mitochondria were isolated from either low- or high-grade human primary brain tumors. Calcium overload conditions (100 or 200 μM), TMZ (300 μM), and BEV (2 mg/mL) were applied to isolated mitochondria from low- and high-grade brain tumors. Following the treatment, mitochondrial function, including reactive oxygen species production, membrane potential changes, and swelling, were determined. The mitochondrial morphology was also examined., Results: In calcium overload conditions, mitochondrial dysfunction was only found to have occurred in low-grade tumors. In TMZ and BEV treatment, BEV, rather than TMZ, caused greater membrane depolarization and mitochondrial swelling in both grades of brain tumors., Conclusions: TMZ and BEV can directly cause the dysfunction of mitochondria isolated from human brain tumors. However, BEV has a greater ability to disturb mitochondrial function in mitochondria isolated from human brain tumors than either TMZ or calcium overload conditions.
- Published
- 2016
- Full Text
- View/download PDF
6. VAP-1 blockade prevents subarachnoid hemorrhage-associated cerebrovascular dilating dysfunction via repression of a neutrophil recruitment-related mechanism.
- Author
-
Xu H, Testai FD, Valyi-Nagy T, N Pavuluri M, Zhai F, Nanegrungsunk D, Paisansathan C, and Pelligrino DA
- Subjects
- Acetylcholine pharmacology, Allylamine pharmacology, Amine Oxidase (Copper-Containing) metabolism, Animals, Arterioles drug effects, Arterioles physiopathology, Cell Adhesion Molecules metabolism, Cerebrovascular Circulation drug effects, Cerebrovascular Circulation physiology, Cholinergic Agonists pharmacology, Disease Models, Animal, Leukocytes drug effects, Leukocytes physiology, Male, Neuroimmunomodulation drug effects, Neuroimmunomodulation physiology, Neutrophil Infiltration physiology, Neutrophils drug effects, Neutrophils physiology, Nitric Oxide Donors pharmacology, Pia Mater blood supply, Pia Mater drug effects, Pia Mater physiopathology, Rats, Sprague-Dawley, Regional Blood Flow drug effects, Regional Blood Flow physiology, S-Nitroso-N-Acetylpenicillamine pharmacology, Subarachnoid Hemorrhage mortality, Subarachnoid Hemorrhage physiopathology, Venules drug effects, Venules physiopathology, Allylamine analogs & derivatives, Amine Oxidase (Copper-Containing) antagonists & inhibitors, Cardiovascular Agents pharmacology, Cell Adhesion Molecules antagonists & inhibitors, Neutrophil Infiltration drug effects, Subarachnoid Hemorrhage drug therapy
- Abstract
Our previous findings indicated that in rats subjected to subarachnoid hemorrhage (SAH), suppression of post-SAH neuroinflammation via vascular adhesion protein-1 (VAP-1) blockade provides significant neuroprotection. We and others have reported that neuroinflammation contributes to cerebral microvascular impairment. Thus, in the present study, we tested the hypotheses that: (1) treatment with LJP-1586, a selective VAP-1 blocker, prevents SAH-associated pial arteriolar dilating dysfunction; and (2) the vasculoprotective effect of LJP-1586 arises from inhibiting SAH-elicited neutrophil recruitment. We utilized an endovascular perforation model of SAH. Rats subjected to SAH were either treated with LJP-1586 or rendered neutropenic via anti-neutrophil-antibody treatment. Findings from these groups were compared to their respective control groups. At 48 h post-SAH, rats were evaluated for neurobehavioral function, pial venular leukocyte trafficking, and pial arteriolar reactivity to topically-applied acetylcholine (ACh) and S-nitroso-N-acetyl penicillamine (SNAP). Pial arteriolar responses decreased at 48 h post-SAH. However, in the presence of LJP-1586, those responses were significantly preserved. Neutrophil-depletion yielded a substantial suppression of SAH-associated leukocyte adhesion and infiltration. This was accompanied by a significant preservation of pial arteriolar dilating function, suggesting a direct link between neutrophil recruitment and the loss of cerebral microvascular reactivity. Moreover, neutrophil depletion also was associated with significant protection of neurobehavioral function. The present findings suggest that attenuating SAH-linked elevation in neutrophil trafficking will protect against the development of microvascular dysfunction and subsequent neurological impairment., (Copyright © 2015 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
7. Current evidence of temozolomide and bevacizumab in treatment of gliomas.
- Author
-
Nanegrungsunk D, Onchan W, Chattipakorn N, and Chattipakorn SC
- Subjects
- Angiogenesis Inhibitors pharmacology, Animals, Antineoplastic Agents therapeutic use, Antineoplastic Agents, Alkylating pharmacology, Antineoplastic Agents, Alkylating therapeutic use, Bevacizumab pharmacology, Brain Neoplasms radiotherapy, Cell Death drug effects, Combined Modality Therapy, Dacarbazine pharmacology, Dacarbazine therapeutic use, Glioma radiotherapy, Humans, Temozolomide, Angiogenesis Inhibitors therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bevacizumab therapeutic use, Brain Neoplasms drug therapy, Dacarbazine analogs & derivatives, Glioma drug therapy, Neoplasm Recurrence, Local drug therapy
- Abstract
Objective: This review article summarizes in vitro, in vivo, and clinical evidence pertaining to temozolomide (TMZ) and bevacizumab (BEV) efficacy and mechanism of action in gliomas., Methods: Relevant publications published before June 2013 in PubMed database were reviewed., Results: Temozolomide and BEV are current chemotherapeutic agents treating patients with high-grade glioma, including glioblastoma. In vitro and in vivo studies have proposed discordant cell death pathways for TMZ as either apoptosis or autophagy using different experimental setting details or cell lines. In addition, BEV may cause cell death through hypoxia-induced autophagy or unspecific indirect effects on cancer cells. The complexity of cancer cells in glioma has contributed to their resistance of both chemotherapies. In clinical trials, overall survival duration in glioma patients with recurrence (8-9 months) is lower than that in newly diagnosed patients (12-15 months)., Conclusion: Our collected data support the addition of radiotherapy, BEV, and other targeted agents to TMZ treatment, indicating prolonged survival duration in newly diagnosed patients. However, the optimal regimen for treating high-grade glioma cannot be concluded without more clinical trials.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.